Showing results (61-70 of 70) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 70 results.
Autoimmunity Reviews|November 1, 2011
Vaccination of patients with auto-immune inflammatory rheumatic diseases requires careful benefit-risk assessmentM Bijl, N Agmon-Levin, J-M Dayer, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 26, 2000
Uncompensated polyuria in a mouse model of Bartter's syndromeN Takahashi, D R Chernavvsky, R A Gomez, et al.
The Journal of Clinical Investigation|May 1, 1985
Aluminum deposition at the osteoid-bone interface. An epiphenomenon of the osteomalacic state in vitamin D-deficient dogsL D Quarles, V W Dennis, H J Gitelman, et al.
Gut|August 16, 2005
Anti-Saccharomyces cerevisiae and antineutrophil cytoplasmic antibodies as predictors of inflammatory bowel diseaseE Israeli, I Grotto, B Gilburd, et al.
Arteriosclerosis (Dallas, Tex.)|January 1, 1985
Regional compliance of brachial artery and saline infusion in patients with arteriosclerosis obliteransJ A Levenson, A C Simon, B E Maarek, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 29, 1997
Modulation of murine systemic lupus erythematosus with peptides based on complementarity determining regions of a pathogenic anti-DNA monoclonal antibodyA Waisman, P J Ruiz, E Israeli, et al.
Alimentary Pharmacology & Therapeutics|August 17, 2002
Discordance between the degree of osteopenia and the prevalence of spontaneous vertebral fractures in Crohn's diseaseR W Stockbrügger, E J Schoon, S Bollani, et al.
Clinical and Experimental Immunology|April 8, 2015
Oral administration of non-absorbable delayed release 6-mercaptopurine is locally active in the gut, exerts a systemic immune effect and alleviates Crohn's disease with low rate of side effects: results of double blind Phase II clinical trialE Israeli, E Goldin, S Fishman, et al.
Alimentary Pharmacology & Therapeutics|December 2, 2010
The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximabU Kopylov, G J Mantzaris, K H Katsanos, et al.
Human Genetics|September 1, 2018
Rare coding variant analysis in a large cohort of Ashkenazi Jewish families with inflammatory bowel diseaseE R Schiff, M Frampton, N Ben-Yosef, et al.
Pageof 7